Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
Inhibition of histone deacetylases (HDACs) leads to growth arrest, differentiation, or apoptosis of tumor cell lines, suggesting HDACs as promising targets for cancer therapy. At present, only one HDAC inhibitor (HDACi) is used in therapy: suberoylanilide hydroxamic acid (SAHA). Here, we describe the synthesis and biological evaluation of a new series of compounds derived from SAHA by substituting short alkyl chains at various positions of the phenyl ring. Such modifications induced variable effects ranging from partial loss of activity to increased potency. Through molecular modeling, we describe a possible interaction between HDAC7 proline 809, a residue that is strictly conserved within class 2 enzymes only, and the amide group of HDACi, while nuclear magnetic resonance experiments indicated that dimethyl m-substitution may stabilize the inhibitor in the active site. Our data provide novel information on the structure-activity relationship of HDACi and suggest new ways for developing second generation SAHA-like molecules.
Equipe SPARTE, UMR CNRS 6026-Université Rennes 1, France, Cedex.
Frédérik
F
Oger
Aurélien
A
Lecorgne
Elisa
E
Sala
Vanessa
V
Nardese
Florence
F
Demay
Soizic
S
Chevance
Danielle C
DC
Desravines
Nataliia
N
Aleksandrova
Rémy
R
Le Guével
Simone
S
Lorenzi
Andrea R
AR
Beccari
Peter
P
Barath
Darren J
DJ
Hart
Arnaud
A
Bondon
Daniele
D
Carettoni
Gérard
G
Simonneaux
Gilles
G
Salbert
D015153:Blotting, Western; D018938:Caco-2 Cells; D048708:Cell Growth Processes / Q000187:drug effects; D004797:Enzyme-Linked Immunosorbent Assay; D056945:Hep G2 Cells; D056572:Histone Deacetylase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D006655:Histone Deacetylases / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D008856:Microscopy, Fluorescence; D008958:Models, Molecular; D013329:Structure-Activity Relationship; D000077337:Vorinostat
D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D000077337:Vorinostat; D006655:Histone Deacetylases